The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density
The Specific Choice of Transrectal Ultrasound-Guided Prostate Biopsy Scheme Based on Prostate Specific Antigen and Prostate Specific Antigen Density
复制标题
基于前列腺特异性抗原及前列腺特异性抗原密度的经直肠超声引导前列腺活检方案的具体选择
DOI：
10.12659/msm.915826
复制
发表时间：
2019-08
影响因子：
3.1
通讯作者：
Xu Yong
中科院分区：
文献类型：
--
作者：
Chen Yue;Jiang Xingkang;Liu Ranlu;Zhang Zhihong;Luo Fei;Qi Shiyong;Xu Yong
Background Although magnetic resonance imaging (MRI)-targeted biopsy and saturation biopsy can improve the accuracy of prostate biopsy, transrectal ultrasound (TRUS)-guided prostate biopsy is still the cornerstone for diagnosis of prostate cancer. However, it is not clear whether it is necessary to perform the same TRUS-guided biopsy scheme for patients with different prostate specific antigen (PSA) or prostate specific antigen density (PSAD) levels. The purpose of this study was to evaluate the optimal core number for specific suspected prostate cancer patients. Material/Methods There were 398 patients who underwent 12-core biopsy scheme, who were included in this retrospective analysis. The 12-core scheme incorporated a classic sextant scheme and 4-core biopsies from the base and middle regions bilaterally. The cancer detection rates of patients with different PSA or PSAD levels between the 12-core, sextant, 4-core, and 2-core biopsy were compared. Results The differences in cancer detection rates between the 12-core biopsy scheme and the sextant biopsy scheme were significant in patients with PSA <20 ng/mL or PSAD <0.3. There were no differences in the cancer detection rates between the 12-core biopsy scheme and the 4-core biopsy scheme in patients with PSA ≤50 ng/mL or PSAD ≤1.0. There were significant differences between 12-core and 2-core scheme when PSA ≤70 ng/mL or PSAD ≤1.5. Conclusions We recommend that the 12-core biopsy should be used for patients with PSA <20 ng/mL or PSAD <0.3. The biopsy scheme in patients with PSA 20–50 ng/mL or PSAD 0.3–1.0 should be considered in combination with DRE and MRI. For patients with PSA >50 ng/mL or PSAD >1.0, we recommend 6-core or 4-core biopsy by comprehensively considering multiple factors. The 2-core biopsy is recommended for patients with PSA >70 ng/mL or PSAD >1.5.
登录
查看更多内容
MR/超声融合引导的活检与超声引导活检的比较，以诊断前列腺癌。
DOI：
10.1001/jama.2014.17942
发表时间：
2015-01-27
期刊：
JAMA
影响因子：
--
作者：
Siddiqui MM;Rais-Bahrami S;Turkbey B;George AK;Rothwax J;Shakir N;Okoro C;Raskolnikov D;Parnes HL;Linehan WM;Merino MJ;Simon RM;Choyke PL;Wood BJ;Pinto PA
通讯作者：
Pinto PA
影响因子：
2.1
作者：
Pepe, Pietro;Aragona, Francesco
通讯作者：
Aragona, Francesco
影响因子：
2.9
作者：
Dai, Bo;Ye, Ding-Wei;Wang, Bo-Hua
通讯作者：
Wang, Bo-Hua
DOI：
10.1056/nejmoa1801993
发表时间：
2018-05-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
23.4
作者：
Elabbady, AA;Khedr, MM
通讯作者：
Khedr, MM